Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Continuous Manufacturing Back In Second Act

Executive Summary

House tries again to promote advanced technology for the return of pharmaceutical manufacturing to the US in post-COVID-19 era.

You may also be interested in...



US COVID-19 Relief Package Boosts Pharma Manufacturing Programs – More To Come?

$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.

US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?

$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.

Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House

Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.

Related Content

Topics

UsernamePublicRestriction

Register

PS142191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel